Javascript must be enabled to continue!
6-OR: PAR2 Downregulates Adipose LPL through MIF—A Novel Adipose Mechanism Contributing to the Development of Hypertriglyceridemia
View through CrossRef
Lipoprotein lipase (LPL) is a key enzyme that hydrolyzes circulating triglycerides to release fatty acid (FA). In adipose tissue, LPL is required for lipid storage. However, it is currently unknown whether alteration of LPL in white adipose tissue (WAT) contributes to the development of hypertriglyceridemia. Our present study indicated that WAT isolated from human obese patients have increased expression of PAR2 which is negatively associated with LPL gene. The reduced LPL expression is also negatively correlated with increased plasma TG levels, suggesting that adipose PAR2 may modulate hyperlipidemia through downregulating LPL. In mice, aging and high palmitic oil diet significantly increased PAR2 expression in adipose tissue which was associated with high plasma MIF levels. PAR2 deficiency attenuates the rise of MIF, suggesting a key role of PAR2 in regulating adipose MIF release. MIF reduced LPL expression and activity in adipocytes. In a MIF overexpressed animal model (Mif lung Tg), high circulating MIF levels inhibited adipose LPL which was associated with increased plasma triglyceride but not fatty acid. Following high palmitic oil diet feeding, adipose LPL expression and activity were also reduced, and this reduction was reversed in PAR2 knockout mice. Interestingly, PAR2 mediated LPL in adipose tissue regulates hypertriglyceridemia through controlling adipocyte lipid storage. In Par2-/- mice, recombinant MIF perfusion recovered high plasma MIF levels, which decreased LPL and attenuated adipocyte lipid storage leading to hypertriglyceridemia. These data together suggest that the downregulation of adipose LPL by PAR2/MIF is an important mechanism for the development of hypertriglyceridemia.
Disclosure
Y.Huang: None. L.Li: None. L.Chen: None. X.Chen: None. P.Gao: None. Y.Qi: None. D.Qi: None.
Funding
Canadian Institutes of Health Research (PJT156116)
American Diabetes Association
Title: 6-OR: PAR2 Downregulates Adipose LPL through MIF—A Novel Adipose Mechanism Contributing to the Development of Hypertriglyceridemia
Description:
Lipoprotein lipase (LPL) is a key enzyme that hydrolyzes circulating triglycerides to release fatty acid (FA).
In adipose tissue, LPL is required for lipid storage.
However, it is currently unknown whether alteration of LPL in white adipose tissue (WAT) contributes to the development of hypertriglyceridemia.
Our present study indicated that WAT isolated from human obese patients have increased expression of PAR2 which is negatively associated with LPL gene.
The reduced LPL expression is also negatively correlated with increased plasma TG levels, suggesting that adipose PAR2 may modulate hyperlipidemia through downregulating LPL.
In mice, aging and high palmitic oil diet significantly increased PAR2 expression in adipose tissue which was associated with high plasma MIF levels.
PAR2 deficiency attenuates the rise of MIF, suggesting a key role of PAR2 in regulating adipose MIF release.
MIF reduced LPL expression and activity in adipocytes.
In a MIF overexpressed animal model (Mif lung Tg), high circulating MIF levels inhibited adipose LPL which was associated with increased plasma triglyceride but not fatty acid.
Following high palmitic oil diet feeding, adipose LPL expression and activity were also reduced, and this reduction was reversed in PAR2 knockout mice.
Interestingly, PAR2 mediated LPL in adipose tissue regulates hypertriglyceridemia through controlling adipocyte lipid storage.
In Par2-/- mice, recombinant MIF perfusion recovered high plasma MIF levels, which decreased LPL and attenuated adipocyte lipid storage leading to hypertriglyceridemia.
These data together suggest that the downregulation of adipose LPL by PAR2/MIF is an important mechanism for the development of hypertriglyceridemia.
Disclosure
Y.
Huang: None.
L.
Li: None.
L.
Chen: None.
X.
Chen: None.
P.
Gao: None.
Y.
Qi: None.
D.
Qi: None.
Funding
Canadian Institutes of Health Research (PJT156116).
Related Results
Macrophage Factor Xa Signaling Promotes Cancer Immune Evasion
Macrophage Factor Xa Signaling Promotes Cancer Immune Evasion
Abstract
Coagulation signaling through protease activated receptors (PARs) participates in inflammation and immunity. In cancer, tissue factor (TF) driven signaling ...
Macrophage migration inhibition factor in peripheral blood and induced sputum in patients with COPD
Macrophage migration inhibition factor in peripheral blood and induced sputum in patients with COPD
BACKGROUND
: Macrophage migration inhibition factor (MIF) induce many inflammatory mediators that involved in the pathogenesis of COPD, we reason that MIF may c...
Excess Coincidences of Hematopoietic Neoplasms
Excess Coincidences of Hematopoietic Neoplasms
Abstract
Introduction:
In recent years diagnostic advances, novel therapies and improved supportive care have led to growing life expectancy of patien...
1598-P: MIF-upregulated CD74 in Liver Contributes to the Development of NAFLD
1598-P: MIF-upregulated CD74 in Liver Contributes to the Development of NAFLD
Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic dysfunctions, such as obesity. Macrophage migration inhibitory factor (MIF), a pro-cytokine, was also identifi...
Abstract 1572: The role of MIF signaling in melanoma progression
Abstract 1572: The role of MIF signaling in melanoma progression
Abstract
Melanoma is the most life-threatening form of skin cancer and although highly curable at the early stages, metastatic melanoma is incurable. One of the earl...
Nouvelles utilisations des isotopes du chrome comme traceurs environnementaux
Nouvelles utilisations des isotopes du chrome comme traceurs environnementaux
La littérature comporte de très nombreux articles présentant l’intérêt de l’étude des fractionnements dépendants de la masse (MDF) des isotopes du Cr, mais également de leurs limit...
The Role of PAR2 in MASLD Progression and HCC Development
The Role of PAR2 in MASLD Progression and HCC Development
Metabolic dysfunction-associated steatotic liver disease (MASLD) has recently become the leading cause of chronic liver disease and can progress to hepatocellular carcinoma (HCC) t...
Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus
Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus
AbstractObjectiveTo demonstrate the binding of bovine lipoprotein lipase (LPL) by IgG from sera obtained from patients with systemic lupus erythematosus (SLE) and other rheumatic d...

